A short half-life of cccDNA offer or ignite hope for hepatitis B cure under nucleos(t)ide analogues treatment.
10.3760/cma.j.cn501113-20200527-00277
- Author:
Lin GAO
1
;
Tian Hao MAO
1
;
Si Wen PENG
1
;
Jie WANG
1
;
Xiang Mei CHEN
1
;
Feng Min LU
2
Author Information
1. Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China.
2. Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China Hepatology Institute, Peking University People's Hospital, Beijing 100044, China.
- Publication Type:Journal Article
- Keywords:
Chronic hepatitis B;
Clinical cure;
Covalently closed circular DNA;
Half-life period;
Hepatitis B virus;
Therapy;
Virologic cure
- MeSH:
Antiviral Agents/therapeutic use*;
DNA, Circular/genetics*;
DNA, Viral;
Half-Life;
Hepatitis B/drug therapy*;
Hepatitis B virus/genetics*;
Hepatitis B, Chronic/drug therapy*;
Humans;
Virus Replication
- From:
Chinese Journal of Hepatology
2022;30(1):99-102
- CountryChina
- Language:Chinese
-
Abstract:
Covalently closed circular DNA (cccDNA) of hepatitis B virus (HBV) is the template for HBV replication. Currently, there is a lack of therapeutic drugs that directly target cccDNA. Therefore, blocking cccDNA supplements as fast as possible and reducing the existing cccDNA is the key to achieving a complete cure of chronic hepatitis B. Previous studies have suggested that cccDNA had a long half-life, but a recent study showed that it only took a few months to update cycle of cccDNA pool, and its number was much less than previously predicted. In the future, with the advent of new antiviral drugs that can completely inhibit HBV replication, it is expected that the cccDNA pool will be completely cleared due to its supplement complete blockade, so as to achieve virological cure of chronic hepatitis B.
